Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14 Junho 2023 - 9:45AM
Palisade Bio (Nasdaq: PALI), a biopharmaceutical company
advancing therapies for acute and chronic gastrointestinal (GI)
complications, today announced that J.D. Finley, Chief Executive
Officer of Palisade Bio will present at the Healthcare Virtual
Conference Part II, presented by Maxim Group LLC and hosted by
M-Vest on Thursday, June 22, 2023 at 11:30 AM ET.
The exponential growth in knowledge and
expertise in science and medicine continues to drive opportunities
in the healthcare space. These include multiple therapeutic
categories and emerging technologies, which presenting companies at
this year’s Maxim Healthcare Conference are focused on, and for
many, that includes key data-driven events in 2023. Maxim Senior
Analysts will host a wide range of biotechnology and medical device
companies in a series of presentations and interactive discussions
with CEOs and key management. Maxim will also be hosting several
topical industry panels that promise to be timely and engaging.
This conference will be live on M-Vest. To
attend, just sign up to become an M-Vest member.
Click Here to Reserve Your Seat.
About Palisade Bio
Palisade Bio is a biopharmaceutical company
focused on developing therapeutics that protect the integrity of
the intestinal barrier. The Company utilizes over three decades of
research and established science that links the role of intestinal
barrier biology with human disease to advance novel therapeutics
that target and improve the integrity of the intestinal
barrier.
The Company’s lead program, LB1148, is a
broad-spectrum serine protease inhibitor that acts to neutralize
digestive enzymes, potentially reducing intestinal damage. In prior
clinical studies, LB1148 has demonstrated positive results in
reducing the incidence and severity of post-surgical abdominal
adhesions and potentially reducing the time to return of
postoperative bowel function. LB1148’s current U.S. Phase 2 study
is evaluating its effectiveness in reducing intra-abdominal
adhesions, accelerating return of gastrointestinal function, and
the prevention of post-operative ileus in subjects undergoing
elective bowel resection (PROFILE).
The Company believes that addressing the
disruption of the intestinal barrier can fundamentally change the
way diseases are treated and establish new standards of patient
care. For more information, please go
to www.palisadebio.com.
Investor Relations ContactJTC Team, LLCJenene
Thomas 833-475-8247PALI@jtcir.com
Palisade Bio (NASDAQ:PALI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Palisade Bio (NASDAQ:PALI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024